Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination.

Safreed-Harmon K, Blach S, Aleman S, Boe Kielland K, Bollerup S, Cooke G, Dalgard O, Dillon JF, Dore GJ, Duberg AS, Grebely J, Midgard H, Porter K, Razavi H, Tyndall M, Weis N, Lazarus JV.

Clin Infect Dis. 2019 Jul 28. pii: ciz714. doi: 10.1093/cid/ciz714. [Epub ahead of print]

PMID:
31352481
2.

Incidence, prevalence and risk factors for hepatitis C in Danish prisons.

Søholm J, Holm DK, Mössner B, Madsen LW, Hansen JF, Weis N, Sauer AP, Awad T, Christensen PB.

PLoS One. 2019 Jul 26;14(7):e0220297. doi: 10.1371/journal.pone.0220297. eCollection 2019.

3.

Too many people with viral hepatitis are diagnosed late - with dire consequences.

Lazarus JV, Picchio C, Dillon JF, Rockstroh JK, Weis N, Buti M.

Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):451-452. doi: 10.1038/s41575-019-0177-z. No abstract available.

PMID:
31320742
4.

Children exposed or unexposed to HIV: weight, height and BMI during the first five years of life. A Danish Nationwide Cohort Study.

Moseholm E, Helleberg M, Sandholdt H, Katzenstein TL, Storgaard M, Pedersen G, Johansen IS, Weis N.

Clin Infect Dis. 2019 Jul 4. pii: ciz605. doi: 10.1093/cid/ciz605. [Epub ahead of print]

PMID:
31271208
5.

Hepatitis E during pregnancy: Maternal and foetal case-fatality rates and adverse outcomes-A systematic review.

Bergløv A, Hallager S, Weis N.

J Viral Hepat. 2019 May 16. doi: 10.1111/jvh.13129. [Epub ahead of print] Review.

PMID:
31095813
6.

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.

Jensen SB, Fahnøe U, Pham LV, Serre SBN, Tang Q, Ghanem L, Pedersen MS, Ramirez S, Humes D, Pihl AF, Filskov J, Sølund CS, Dietz J, Fourati S, Pawlotsky JM, Sarrazin C, Weis N, Schønning K, Krarup H, Bukh J, Gottwein JM.

Hepatology. 2019 Sep;70(3):771-787. doi: 10.1002/hep.30647. Epub 2019 Jun 5.

PMID:
30964552
7.

The Prevalence of Human Immunodeficiency Virus Coinfection Among Patients Newly Diagnosed With Chronic Hepatitis B or C in Denmark: A Nationwide Cohort Study.

Hallager S, Lundh A, Ladelund S, Gerstoft J, Laursen AL, Clausen MR, Balslev U, Weis N.

Open Forum Infect Dis. 2018 Nov 21;5(12):ofy310. doi: 10.1093/ofid/ofy310. eCollection 2018 Dec.

8.

Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail.

Neesgaard B, Ruhwald M, Krarup HB, Weis N.

PLoS One. 2018 Jul 31;13(7):e0201629. doi: 10.1371/journal.pone.0201629. eCollection 2018.

9.

Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.

Sølund C, Andersen ES, Mössner B, Laursen AL, Røge BT, Kjær MS, Gerstoft J, Christensen PB, Pedersen MS, Schønning K, Fahnøe U, Bukh J, Weis N.

Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1177-1186. doi: 10.1097/MEG.0000000000001192.

PMID:
29994874
10.

Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.

Colagrossi L, Hermans LE, Salpini R, Di Carlo D, Pas SD, Alvarez M, Ben-Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Lepej SZ, Weis N, Yalcinkaya T, Boucher CAB, Wensing AMJ, Perno CF, Svicher V; HEPVIR working group of the European Society for translational antiviral research (ESAR).

BMC Infect Dis. 2018 Jun 1;18(1):251. doi: 10.1186/s12879-018-3161-2.

11.

Analytical performance of the Hologic Aptima HBV Quant Assay and the COBAS Ampliprep/COBAS TaqMan HBV test v2.0 for the quantification of HBV DNA in plasma samples.

Schønning K, Johansen K, Nielsen LG, Weis N, Westh H.

J Clin Virol. 2018 Jul;104:83-88. doi: 10.1016/j.jcv.2018.05.007. Epub 2018 May 18.

PMID:
29783147
12.

Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation.

Sølund C, Hallager S, Pedersen MS, Fahnøe U, Ernst A, Krarup HB, Røge BT, Christensen PB, Laursen AL, Gerstoft J, Bélard E, Madsen LG, Schønning K, Pedersen AG, Bukh J, Weis N; DANHEP group.

Scand J Gastroenterol. 2018 Jun - Jul;53(7):849-856. doi: 10.1080/00365521.2018.1467963. Epub 2018 May 2.

PMID:
29720023
13.

Anti-müllerian hormone levels are reduced in women living with human immunodeficiency virus compared to control women: a case-control study from Copenhagen, Denmark.

Wessman M, Korsholm AS, Bentzen JG, Andersen AN, Ahlström MG, Katzenstein TL, Weis N.

J Virus Erad. 2018 Apr 1;4(2):123-127.

14.

Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.

Safreed-Harmon K, Hetherington KL, Aleman S, Alho H, Dalgard O, Frisch T, Gottfredsson M, Weis N, Lazarus JV; Hep-Nordic Study Group.

PLoS One. 2018 Jan 30;13(1):e0190146. doi: 10.1371/journal.pone.0190146. eCollection 2018.

15.

Late Presentation for Care Among Patients With Chronic Hepatitis C: Prevalence and Risk Factors.

Hansen JF, Hallager S, Øvrehus A, Weis N, Brehm Christensen P, Pedersen C.

Open Forum Infect Dis. 2017 Nov 22;5(1):ofx257. doi: 10.1093/ofid/ofx257. eCollection 2018 Jan.

16.

Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response.

Hallager S, Ladelund S, Christensen PB, Kjær M, Thorup Roege B, Grønbæk KE, Belard E, Barfod TS, Madsen LG, Gerstoft J, Tarp B, Krarup HB, Weis N.

Clin Epidemiol. 2017 Oct 24;9:501-516. doi: 10.2147/CLEP.S132072. eCollection 2017.

17.

Measurement of GPCR-G protein activity in living cells.

Ratnayake K, Kankanamge D, Senarath K, Siripurapu P, Weis N, Tennakoon M, Payton JL, Karunarathne A.

Methods Cell Biol. 2017;142:1-25. doi: 10.1016/bs.mcb.2017.07.008. Epub 2017 Sep 19.

PMID:
28964328
18.

[The significance of HIV to bone mineral density].

Wessman M, Weis N, Katzenstein TL, Lebech AM, Thorsteinsson K, Hansen AE, Jensen JB.

Ugeskr Laeger. 2017 Sep 4;179(36). pii: V05170420. Review. Danish.

PMID:
28874254
19.

Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: A nationwide cohort study.

Hallager S, Ladelund S, Kjaer M, Madsen LG, Belard E, Laursen AL, Gerstoft J, Røge BT, Grønbaek KE, Krarup HB, Christensen PB, Weis N.

J Viral Hepat. 2018 Jan;25(1):47-55. doi: 10.1111/jvh.12764. Epub 2017 Sep 22.

PMID:
28750141
20.

Analytical and clinical performance of the Hologic Aptima HCV Quant Dx Assay for the quantification of HCV RNA in plasma samples.

Schønning K, Pedersen MS, Johansen K, Landt B, Nielsen LG, Weis N, Westh H.

J Virol Methods. 2017 Oct;248:159-165. doi: 10.1016/j.jviromet.2017.07.006. Epub 2017 Jul 19.

PMID:
28732692
21.

Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.

Dalgard O, Weiland O, Noraberg G, Karlsen L, Heggelund L, Färkkilâ M, Balslev U, Belard E, Øvrehus A, Skalshøi Kjær M, Krarup H, Thorup Røge B, Hallager S, Madsen LG, Lund Laursen A, Lagging M, Weis N.

PLoS One. 2017 Jul 13;12(7):e0179764. doi: 10.1371/journal.pone.0179764. eCollection 2017.

22.

Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review.

Neesgaard B, Ruhwald M, Weis N.

World J Hepatol. 2017 May 18;9(14):677-688. doi: 10.4254/wjh.v9.i14.677. Review.

23.

Bacterial vaginosis, human papilloma virus and herpes viridae do not predict vaginal HIV RNA shedding in women living with HIV in Denmark.

Wessman M, Thorsteinsson K, Jensen JS, Storgaard M, Rönsholt FF, Johansen IS, Pedersen G, Nørregård Nielsen L, Bonde J, Katzenstein TL, Weis N, Lebech AM.

BMC Infect Dis. 2017 May 31;17(1):376. doi: 10.1186/s12879-017-2477-7.

24.

Assessment of mode of delivery and predictors of emergency caesarean section among women living with HIV in a matched-pair setting with women from the general population in Denmark, 2002-2014.

Ørbaek M, Thorsteinsson K, Helleberg M, Moseholm E, Katzenstein TL, Storgaard M, Johansen IS, Pedersen G, Weis N, Lebech AM.

HIV Med. 2017 Nov;18(10):736-747. doi: 10.1111/hiv.12519. Epub 2017 May 24.

PMID:
28544321
25.

Methodological considerations when calculating person-time at risk for patients with chronic hepatitis C undergoing antiviral treatment.

Hallager S, Ladelund S, Weis N.

J Hepatol. 2017 Aug;67(2):427-428. doi: 10.1016/j.jhep.2017.02.035. Epub 2017 Apr 21. No abstract available.

PMID:
28435039
26.

A Danish nationwide questionnaire study of hepatitis B virus screening before immunosuppressive therapy.

Bunyoz KI, Krarup H, Weis N.

Dan Med J. 2017 Mar;64(3). pii: A5341.

PMID:
28260595
27.

The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.

Young J, Weis N, Hofer H, Irving W, Weiland O, Giostra E, Pascasio JM, Castells L, Prieto M, Postema R, Lefevre C, Evans D, Bucher HC, Calleja JL.

BMC Infect Dis. 2017 Jan 7;17(1):45. doi: 10.1186/s12879-016-2106-x.

28.

Mortality Rates in Patients With Chronic Hepatitis C and Cirrhosis Compared With the General Population: A Danish Cohort Study.

Hallager S, Brehm Christensen P, Ladelund S, Rye Clausen M, Lund Laursen A, Møller A, Schlicthting P, Galmstrup Madsen L, Gerstoft J, Lunding S, Elmegaard Grønbæk K, Bygum Krarup H, Weis N.

J Infect Dis. 2017 Jan 15;215(2):192-201. doi: 10.1093/infdis/jiw527.

PMID:
27803168
29.

Vertical transmission of hepatitis B virus during pregnancy and delivery in Denmark.

Weis N, Cowan S, Hallager S, Dröse S, Kristensen LH, Grønbæk K, Jensen J, Gerstoft J, Madsen LG, Clausen MR, Lunding S, Tarp BD, Barfod TS, Sloth S, Holm DK, Jensen J, Krarup H.

Scand J Gastroenterol. 2017 Feb;52(2):178-184. doi: 10.1080/00365521.2016.1244704. Epub 2016 Oct 31. Erratum in: Scand J Gastroenterol. 2017 Feb;52(2):i.

PMID:
27796133
30.

Hospital admission among HIV-exposed uninfected children compared with HIV-unexposed children.

Moseholm E, Helleberg M, Nordly SB, Rosenfeldt V, Storgaard M, Pedersen G, Johansen IS, Lunding S, Weis N, Katzenstein TL.

AIDS. 2016 Nov 13;30(17):2697-2706.

PMID:
27536980
31.

How Physician Assistant Programs Use the CASPA Personal Statement in Their Admissions Process.

Lopes JE Jr, Badur M, Weis N.

J Physician Assist Educ. 2016 Jun;27(2):51-5. doi: 10.1097/JPA.0000000000000065.

PMID:
27123595
32.

Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection.

Pedersen J, Lundbo LF, Krarup H, Bukh J, Weis N.

J Med Virol. 2016 Oct;88(10):1791-803. doi: 10.1002/jmv.24537. Epub 2016 May 16.

PMID:
27027386
33.

[Indicator-based HIV testing].

Hansen BR, Andersen ÅB, Koch A, Ravn P, Larsen CS, Weis N, Gerstoft J.

Ugeskr Laeger. 2015 Sep 7;177(37):V03150266. Review. Danish.

PMID:
26376241
34.

Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).

Hermans LE, Svicher V, Pas SD, Salpini R, Alvarez M, Ben Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Weis N, Yalcinkaya T, Lepej SZ, Perno C, Boucher CA, Wensing AM; HEPVIR Working Group of the European Society for Translational Antiviral Research.

J Infect Dis. 2016 Jan 1;213(1):39-48. doi: 10.1093/infdis/jiv363. Epub 2015 Jul 1.

PMID:
26136470
35.

Perception of sexuality and fertility in women living with HIV: a questionnaire study from two Nordic countries.

Wessman M, Aho I, Thorsteinsson K, Storgaard M, Johansen IS, Lunding S, Pedersen G, Lebech AM, Kivelä P, Helleberg M, Katzenstein TL, Weis N.

J Int AIDS Soc. 2015 Jun 1;18:19962. doi: 10.7448/IAS.18.1.19962. eCollection 2015.

36.

Glycemic Variability Is Associated with Frequency of Blood Glucose Testing and Bolus: Post Hoc Analysis Results from the ProAct Study.

Pfützner A, Weissmann J, Mougiakakou S, Daskalaki E, Weis N, Ziegler R.

Diabetes Technol Ther. 2015 Jun;17(6):392-7. doi: 10.1089/dia.2014.0278. Epub 2015 Mar 3.

37.

Increased concentrations of the soluble mannose receptor in serum from patients with pneumococcal bacteraemia, and prediction of survival.

Rødgaard-Hansen S, Rafique A, Weis N, Wejse C, Nielsen H, Pedersen SS, Møller HJ, Kronborg G.

Infect Dis (Lond). 2015 Apr;47(4):203-8. doi: 10.3109/00365548.2014.984321. Epub 2015 Feb 4.

PMID:
25650730
38.

Risk of all-type cancer, hepatocellular carcinoma, non-Hodgkin lymphoma and pancreatic cancer in patients infected with hepatitis B virus.

Andersen ES, Omland LH, Jepsen P, Krarup H, Christensen PB, Obel N, Weis N; DANVIR Cohort Study.

J Viral Hepat. 2015 Oct;22(10):828-34. doi: 10.1111/jvh.12391. Epub 2015 Feb 4.

PMID:
25650146
39.

Genetic variants in the apoptosis gene BCL2L1 improve response to interferon-based treatment of hepatitis C virus genotype 3 infection.

Clausen LN, Weis N, Ladelund S, Madsen L, Lunding S, Tarp B, Christensen PB, Krarup HB, Møller A, Gerstoft J, Clausen MR, Benfield T; DANHEP group.

Int J Mol Sci. 2015 Feb 2;16(2):3213-25. doi: 10.3390/ijms16023213.

40.

Influence of hepatitis C virus and IL28B genotypes on liver stiffness.

Lundbo LF, Clausen LN, Weis N, Schønning K, Rosenørn L, Benfield T, Christensen PB.

PLoS One. 2014 Dec 29;9(12):e115882. doi: 10.1371/journal.pone.0115882. eCollection 2014.

41.

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.

Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B.

Lancet. 2015 Mar 21;385(9973):1087-97. doi: 10.1016/S0140-6736(14)61793-1. Epub 2014 Nov 11.

PMID:
25467560
42.

Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.

Sølund C, Krarup H, Ramirez S, Thielsen P, Røge BT, Lunding S, Barfod TS, Madsen LG, Tarp B, Christensen PB, Gerstoft J, Laursen AL, Bukh J, Weis N; DANHEP group.

PLoS One. 2014 Dec 1;9(12):e113034. doi: 10.1371/journal.pone.0113034. eCollection 2014.

43.

[Increased risk of hepatocellular carcinoma in patients with chronic hepatitis C].

Hallager S, Weis N.

Ugeskr Laeger. 2014 Oct 6;176(41). pii: V02140132. Review. Danish.

PMID:
25331666
44.

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA.

Gastroenterology. 2015 Feb;148(2):355-366.e1. doi: 10.1053/j.gastro.2014.10.007. Epub 2014 Oct 13.

PMID:
25311593
45.

[Chronic hepatitis C presenting with a diagnosis of hepatocellular carcinoma].

Hallager S, Weis N.

Ugeskr Laeger. 2014 Aug 11;176(33). pii: V02140131. Danish.

PMID:
25293410
46.

Første orale hepatitis C-behandling er markedsført.

Christensen PB, Weis N, Laursen AL.

Ugeskr Laeger. 2014 Jun 2;176(11A). pii: V66248. Danish. No abstract available.

PMID:
25186702
47.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S.

Gut. 2015 Jun;64(6):948-56. doi: 10.1136/gutjnl-2014-307498. Epub 2014 Jul 30.

PMID:
25080450
48.

Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar.

Karsdal MA, Krarup H, Sand JM, Christensen PB, Gerstoft J, Leeming DJ, Weis N, Schaffalitzky de Muckadell OB, Krag A.

Aliment Pharmacol Ther. 2014 Aug;40(3):233-49. doi: 10.1111/apt.12820. Epub 2014 Jun 9. Review.

49.

Strategies to manage hepatitis C virus (HCV) disease burden.

Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, El-Sayed MH, Ergör G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Guimarães Pessôa M, Hézode C, Hindman SJ, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho RT, Marotta P, Mauss S, Mendes Correa MC, Moreno C, Müllhaupt B, Myers RP, Nemecek V, Øvrehus AL, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Sarrazin C, Semela D, Sherman M, Shiha GE, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, Gower E.

J Viral Hepat. 2014 May;21 Suppl 1:60-89. doi: 10.1111/jvh.12249.

PMID:
24713006
50.

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.

Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C.

J Viral Hepat. 2014 May;21 Suppl 1:34-59. doi: 10.1111/jvh.12248.

PMID:
24713005

Supplemental Content

Support Center